ANALYST-UPGRADE ·Filed Jul 7, 2026

REGN

REGENERON PHARMACEUTICALS, INC.
MIXED
Impact 2/10
Processed2mo ago SECanalyst-REGN-benchmar-20260707
Benchmark double upgrade: Hold → Buy
Actionable Insight ◆ Mixed

The double upgrade is a bullish catalyst, but the absurdly low $185 target undermines its credibility. Traders should wait for clarification from Benchmark or a revised target before acting on this call. The consensus bullish view and upcoming earnings on July 30 add to the uncertainty.

DirectionMixed
Final — all horizons settled through T+60d ⚠ clustered
REGN ▲ +12.13% at T+60d
NEUTRAL call ✓ call won +12.13% · α vs SPY +10.14% · entry $676.23 → $758.27
Entry anchored
Jul 6, 03:59 PM ET
via exchange tick
T+1d
-1.97%
call -1.97% · α -1.67%
$662.88
settled 3mo ago
T+5d
-2.97%
call -2.97% · α -3.52%
$656.12
settled 3mo ago
T+20d
+12.28%
call +12.28% · α +10.94%
$759.24
settled 8w ago
T+60d
+12.13%
call +12.13% · α +10.14%
$758.27
settled 2d ago

Price Chart

Loading chart...

Executive Summary

Benchmark double-upgraded REGN from Hold to Buy on July 7, 2026, but set a price target of $185, implying a 71.5% downside from the current $649.81 — an extreme divergence from the consensus mean of $833.31. The firm's 54% accuracy on 1,703 calls is average, and its average return of 6% is in line with peers. Consensus remains heavily bullish: 71% Buy (27 of 38 analysts), 29% Hold, 0% Sell. The mean target of $833.31 offers 28.2% upside, with a high of $1,000 and low of $641. Benchmark's $185 target sits far below the lowest Street estimate. 30-day analyst momentum shows 1 upgrade and 0 downgrades, while EPS revisions are net positive for the next quarter and current year. Insider sales by Arthur F Ryan (~$51K on May 1) are small and non-informative; a congressional buy by Ro Khanna adds a minor bullish signal. The double upgrade is a strong directional call, but the contradictory price target creates confusion — traders should treat this as an outlier until clarified.

Impact Score

Base Score
2/7
LLM Adjustment
+0
Final Score
2/10

Consensus & Targets

Buy / Strong Buy
27 (71%)
Hold
11
Sell / Strong Sell
0
Total Analysts
28
Mean PT
$833.31
Median PT
$852.50
High PT
$1,000.00
Low PT
$641.00
Current Price
$649.81
Implied Upside
+28.2%

Of 38 analysts covering REGN, 9 rate it Strong Buy, 18 Buy, 11 Hold, 0 Sell, and 0 Strong Sell — a 71% Buy-side consensus. The consensus is firmly bullish, with no sell ratings. Benchmark's upgrade aligns with the majority view, but its price target is an extreme outlier.

The consensus mean price target is $833.31, median $852.50, high $1,000, and low $641. At $649.81, REGN trades 22% below the low end of the Street range. Implied upside to the mean is 28.2%. Benchmark's $185 target is 71.5% below the current price and 77.8% below the consensus low — the most bearish target by a wide margin.

Recent Analyst Activity

DateFirmActionRatingPrice Target
2026-07-07Truist SecuritiesmaintainBuy$769.00
2026-07-07BenchmarkupgradeBuy$185.00
2026-07-06HSBCmaintainBuy—
2026-07-06Cantor FitzgeraldmaintainOverweight$750.00
2026-05-19Canaccord GenuitymaintainBuy$875.00
2026-05-18BMO CapitalmaintainOutperform$730.00
2026-05-18Truist SecuritiesmaintainBuy$778.00
2026-05-18JP MorganmaintainOverweight$850.00
2026-05-18Piper SandlermaintainOverweight$855.00
2026-05-18Wells FargomaintainEqual-Weight$700.00

In the past 30 days, REGN has received 1 upgrade (Benchmark) and 0 downgrades. EPS revisions show a mixed but slightly positive trend: for the current quarter, 9 upward vs 11 downward revisions in 30 days; for the next quarter, 13 up vs 6 down; for the current fiscal year, 17 up vs 8 down. Estimates are being revised higher for the forward periods.

Firm Track Record — Benchmark

Benchmark accuracy: 54% on 1703 calls | avg return: 6%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 15 firms with ≥5 scored calls.

FirmAccuracyCallsAvg Returnvs Average
UBS67%4/65.1%top tier
Canaccord Genuity57%4/79.4%above average
TD Cowen50%1/23.1%below average
Bernstein50%1/26.2%below average
Cantor Fitzgerald50%4/8-4.5%below average
BMO Capital50%3/6-3.7%below average
Morgan Stanley50%5/104.1%below average
Goldman Sachs50%1/2-3.6%below average
Leerink Partners50%1/2-23.7%below average
Evercore ISI Group50%1/2-4.9%below average

Benchmark has a 54% accuracy rate on 1,703 scored calls with an average return of 6%. This is in line with the peer average. Among firms covering REGN, UBS leads with 67% accuracy (6 calls), while RBC Capital lags at 33% (18 calls). Benchmark's track record does not suggest exceptional forecasting ability for this name.

Earnings Estimates

Next earnings: Jul 30, 2026

PeriodEPS Est.EPS RangeRevenueRevisions (7d)
0q$10.81$7.69 — $13.25$3.8B↑1 ↓0
+1q$13.07$8.88 — $17.10$4.2B↑1 ↓0
0y$46.21$37.15 — $53.61$15.9B↑2 ↓0
+1y$48.10$40.93 — $60.05$17.6B↑0 ↓0

Cross-Platform Signals

Insider Trades (90d)
0 buys / 5 sells
Congressional
Ro Khanna (democrat) — buy $1,001 - $15,000
Institutional
Empowered Funds, LLC — trim (-52.8%)
Institutional
Walleye Capital LLC — near_exit (-88.7%)
Institutional
GATEWAY INVESTMENT ADVISERS LLC — add (67.9%)

Insider activity shows only sales: Arthur F Ryan sold ~$51K worth of shares on May 1, 2026 — a small, routine-looking transaction with limited predictive power. A single congressional buy by Rep. Ro Khanna (Democrat, $1K-$15K) on April 13 provides a minor bullish signal. Institutional moves are mixed: Empowered Funds trimmed 52.8%, while INTECH added 33%. No short interest data is available. The analyst upgrade is not strongly corroborated by other signals.

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

Report based on filing metadata.

26 reports for REGN
Performance horizon
85% Hit rate 11 of 13 directional calls best @ T+60▲ +26.47%May 21, 2026
Filters
Rows
Reports for REGN — sortable, filterable
TypeNow
Oct 1, 2026
1d ago
ANALYST-UPGRADE
BULLISH ★ 4/10
—awaiting T+20——
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 2/10
$843.47 $735.20▼ −12.84%▼ −11.65%$735.20 (−12.84%)
Aug 24, 2026
5w ago
Court Ruling
BULLISH ★ 5/10
$828.50 $803.90▼ −2.97%▼ −4.28%$735.20 (−11.26%)
Aug 20, 2026
6w ago
Press Release
NEUTRAL ★ 5/10
$826.64 $784.85▼ −5.06%▼ −5.06%$735.20 (−11.06%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$797.99 $793.26▼ −0.59%▲ +1.30%$735.20 (−7.87%)
Aug 11, 2026
7w ago
Court Ruling
BULLISH ★ 5/10
$797.00 $807.65▲ +1.34%▲ +2.40%$735.20 (−7.75%)
Jul 30, 2026
9w ago
8-K
BULLISH ★ 7/10
$738.34 $807.71▲ +9.40%▲ +5.43%$735.20 (−0.43%)
Jul 30, 2026
9w ago
Press Release
BULLISH ★ 7/10
$738.34 $807.71▲ +9.40%▲ +5.43%$735.20 (−0.43%)
Jul 27, 2026
9w ago
Press Release
BEARISH ★ 6/10
$695.18 $833.56▼ −19.91%▼ −16.52%$735.20 (−5.76%)
Jul 17, 2026
11w ago
Press Release
NEUTRAL ★ 3/10
$676.69 $800.70▲ +18.33%▲ +13.88%$735.20 (+8.65%)
Showing 10 of 26

US Market Status

Market Closed — Opens Mon (64h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jul 7, 2026